©The Author(s) 2004.
World J Gastroenterol. Aug 15, 2004; 10(16): 2379-2382
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Table 3 Base-line characteristics of the patients (n, %)
| Characteristic | DA-9601 180 mg (n = 186) | DA-9601 360 mg (n = 140) | Cetraxate 600 mg (n = 186) |
| Male sex | 89 (47.9) | 72 (51.4) | 92 (49.5) |
| Age(yr) | 45.9 ± 11.2 | 44.6 ± 12.1 | 46.4 ± 11.5 |
| History < 1 wk | 3 (1.6) | 1 (0.7) | 3 (1.6) |
| 1–4 wk | 31 (16.7) | 28 (20.0) | 29 (15.6) |
| > 4 wk | 98 (52.7) | 27 (19.3) | 97 (52.2) |
| Unknown | 54 (29.0) | 84 (60.0) | 57 (30.7) |
| Type Erosion | 186 (100) | 140 (100) | 186 (100) |
| Bleeding | 8 (4.3) | 4 (2.9) | 10 (5.4) |
| Redness | 51 (27.4) | 47 (33.6) | 44 (23.7) |
| Edema | 2 (1.1) | 10 (7.1) | 5 (2.7) |
| Grade Mild | 14 (7.5) | 18 (12.9) | 21 (11.3) |
| Moderate | 50 (26.9) | 40 (28.6) | 54 (29.0) |
| Severe | 122 (65.6) | 82 (58.6) | 111 (59.7) |
- Citation: Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial. World J Gastroenterol 2004; 10(16): 2379-2382
- URL: https://www.wjgnet.com/1007-9327/full/v10/i16/2379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i16.2379